Trinity Biotech (TRIB) Stock Price

Trinity Biotech Price

NASDAQ·CLOSED
5.82
​
Market closed

Revenue at Trinity Biotech has contracted by 5.1% per year over the past 19 years to 43.79 M USD. Earnings per share have grown at 25.1% per year over the last 15 years. For Trinity Biotech, the net margin of -85.4% is down versus 1.1% a few years ago. At today's price the dividend yield works out to roughly 566.52%. The consensus 12-month price target for Trinity Biotech is 4.08 USD, about 30.0% below where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

Trinity Biotech stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech business model & stock analysis

Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings.

Frequently asked questions about Trinity Biotech

Analysts currently set an average price target of 4.08 USD for the Trinity Biotech stock (median: 4.08 USD), implying -30.0 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Trinity Biotech stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Trinity Biotech to generate revenue of 59.50 M USD and earnings per share of -1.03 USD.

Converted at the current exchange rate, the Trinity Biotech share trades at 5.31 EUR (5.82 USD).

The Trinity Biotech share (TRIB) is listed on 4 stock exchanges, including: NASDAQ (TRIB), Frankfurt (TRBA.F), München (TRBA.MU), Düsseldorf (TRBA.DU).

The expected revenue of Trinity Biotech is 59.50 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Trinity Biotech is -385.00 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Trinity Biotech is currently -5.66. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Trinity Biotech stock.

The price-to-sales ratio (P/S) of Trinity Biotech is currently 36.63. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Trinity Biotech stock.

The Eulerpool Quality Score for Trinity Biotech is 4/10.

The ISIN of Trinity Biotech is US8964385046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Trinity Biotech is A0ET3S. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Trinity Biotech is TRIB. The ticker symbol is used to trade Trinity Biotech shares on the stock exchange.

Fair ValueTerminal
6.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
75,621.76 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Ireland
Currency
USD
Initial public offering
Oct 21, 1992
ISIN
US8964385046
Cusip
896438306
Sedol
B09WQ53
Market capitalization
2.06 B USDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-5.66
P/Se
36.63
EV/EBIT
—
P/B Ratio
436.55
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-56.63 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
594.17 %
Payout Ratio
4,846.38 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
25.00 %
Last updated Nov 20, 2026, 4:27 AM

Trinity Biotech Peer Group

Trinity Biotech Ticker

DÜSSELDORF · TRBA.DUFRANKFURT · TRBA.FMUNICH · TRBA.MUNASDAQ · TRIB